Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after a debate over pot'l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics occurred around the word "relapsed".

The analyst believes little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed patients are healthier than refractory patients. Analysis suggests otherwise and we think FDA should come to a similar conclusion.

No change to the price target of $72.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $51.69 yesterday.